Bjork-Shiley court decision
This article was originally published in The Gray Sheet
Executive Summary
Pfizer plans to "seek relief" in the California Supreme Court from an Orange County Superior Court decision that allows non- California U.S. residents with working Bjork-Shiley heart valves to litigate in California. On Dec. 30, the California Court of Appeals rejected a Pfizer writ seeking reversal of the lower court's decision ("The Gray Sheet" Dec. 7, In Brief). The appeals court also denied Pfizer's request to stop proceedings on all suits filed in California courts against Pfizer's Shiley unit by out-of-state recipients. Pfizer estimates that 225 non-California valve recipients have not yet entered settlements....
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.